142 related articles for article (PubMed ID: 38429725)
1. LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study.
Wonglhow J; Sunpaweravong P; Sathitruangsak C; Dechaphunkul A
BMC Cancer; 2024 Mar; 24(1):281. PubMed ID: 38429725
[TBL] [Abstract][Full Text] [Related]
2. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Qin S; Bai Y; Lim HY; Thongprasert S; Chao Y; Fan J; Yang TS; Bhudhisawasdi V; Kang WK; Zhou Y; Lee JH; Sun Y
J Clin Oncol; 2013 Oct; 31(28):3501-8. PubMed ID: 23980077
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
4. The Performance of a Survival Nomogram and Albumin-Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4.
Wonglhow J; Sunpaweravong P; Sathitruangsak C; Dechaphunkul A
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673030
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Qin S; Cheng Y; Liang J; Shen L; Bai Y; Li J; Fan J; Liang L; Zhang Y; Wu G; Rau KM; Yang TS; Jian Z; Liang H; Sun Y
Oncologist; 2014 Nov; 19(11):1169-78. PubMed ID: 25223462
[TBL] [Abstract][Full Text] [Related]
8. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial.
Shi J; Sun J; Liu C; Chai Z; Wang N; Zhang H; Cheng S
Trials; 2019 Apr; 20(1):245. PubMed ID: 31036040
[TBL] [Abstract][Full Text] [Related]
9. A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
Sun J; Liu C; Shi J; Wang N; Jiang D; Mao F; Gu J; Zhou L; Shen L; Lau WY; Cheng S
Chin Med J (Engl); 2022 Oct; 135(19):2338-2343. PubMed ID: 36103975
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
[No Abstract] [Full Text] [Related]
11. Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4.
Qin S; Zhang X; Guo W; Feng J; Zhang T; Men L; He J
Asian Pac J Cancer Prev; 2017 May; 18(5):1225-1232. PubMed ID: 28610406
[TBL] [Abstract][Full Text] [Related]
12. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
13. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
Oranratnachai S; Rattanasiri S; Sirachainan E; Tansawet A; Raunroadroong N; McKay GJ; Attia J; Thakkinstian A
Cancer Med; 2023 Feb; 12(3):3046-3053. PubMed ID: 36082831
[TBL] [Abstract][Full Text] [Related]
15. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
18. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Sun J; Mao F; Liu C; Zhang F; Jiang D; Guo W; Huo L; Zhou L; Lau WY; Shi J; Cheng S
Signal Transduct Target Ther; 2023 Sep; 8(1):368. PubMed ID: 37752117
[TBL] [Abstract][Full Text] [Related]
19. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Zhang P; Wen F; Li Q
Dig Liver Dis; 2016 Dec; 48(12):1492-1497. PubMed ID: 27486048
[TBL] [Abstract][Full Text] [Related]
20. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
Lin CC; Yang TS; Yen CJ; Cheng R; Liu J; Hsu C
Oncologist; 2020 Dec; 25(12):e1921-e1929. PubMed ID: 33017497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
